Revance Therapeutics (NASDAQ: RVNC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.910 | -0.940 | -0.0300 | ||||
REV | 24.010M | 25.261M | 1.251M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Revance Therapeutics (NASDAQ: RVNC) through any online brokerage.
Other companies in Revance Therapeutics’s space includes: Theravance Biopharma (NASDAQ:TBPH), CinCor Pharma (NASDAQ:CINC), Sundial Growers (NASDAQ:SNDL), Reata Pharmaceuticals (NASDAQ:RETA) and Supernus Pharmaceuticals (NASDAQ:SUPN).
The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Barclays on Tuesday, October 26, 2021. The analyst firm set a price target for 22.00 expecting RVNC to rise to within 12 months (a possible 43.98% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Revance Therapeutics (NASDAQ: RVNC) is $15.28 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Revance Therapeutics.
Revance Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Revance Therapeutics.
Revance Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.